Bioventus Inc. (NYSE:BVS) CFO Sells $29,333.75 in Stock

Bioventus Inc. (NYSE:BVS - Get Free Report) CFO Mark Leonard Singleton sold 3,875 shares of the stock in a transaction on Friday, April 11th. The shares were sold at an average price of $7.57, for a total transaction of $29,333.75. Following the sale, the chief financial officer now directly owns 141,088 shares of the company's stock, valued at $1,068,036.16. The trade was a 2.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, March 24th, Mark Leonard Singleton sold 5,479 shares of Bioventus stock. The shares were sold at an average price of $9.79, for a total value of $53,639.41.
• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The stock was sold at an average price of $10.19, for a total value of $66,214.62.

Bioventus Stock Up 0.5 %

Shares of NYSE BVS traded up $0.04 during mid-day trading on Friday, hitting $7.82. 323,591 shares of the stock traded hands, compared to its average volume of 446,547. The stock has a fifty day moving average price of $9.29 and a 200-day moving average price of $10.60. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company has a market cap of $640.80 million, a price-to-earnings ratio of -12.82 and a beta of 0.92. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Hedge Funds Weigh In On Bioventus

Institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC grew its stake in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock worth $36,000 after buying an additional 1,786 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in shares of Bioventus in the fourth quarter worth $38,000. GAMMA Investing LLC increased its holdings in shares of Bioventus by 3,228.7% during the first quarter. GAMMA Investing LLC now owns 5,792 shares of the company's stock valued at $53,000 after acquiring an additional 5,618 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Bioventus in the 4th quarter worth about $75,000. Finally, Quantbot Technologies LP purchased a new stake in Bioventus during the 4th quarter valued at about $103,000. Institutional investors own 62.94% of the company's stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.